

Weidong Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/481566/publications.pdf>

Version: 2024-02-01

147
papers

8,720
citations

44069

48
h-index

53230

85
g-index

154
all docs

154
docs citations

154
times ranked

12214
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1â€2 trial. <i>Leukemia</i> , 2022, 36, 189-196.	7.2	45
2	Optimal model establishment of whole-process management data for CAR-T therapy in Chinaâ€”how should this be done?. <i>Cellular and Molecular Immunology</i> , 2022, 19, 122-124.	10.5	0
3	CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. <i>Blood Advances</i> , 2022, 6, 2695-2699.	5.2	11
4	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. <i>Nature Cancer</i> , 2022, 3, 108-121.	13.2	150
5	Inducing immunogenic cell death in immuno-oncological therapies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 1-10.	2.2	8
6	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 98.	17.1	19
7	Epiâ€immunotherapy for cancers: rationales of epiâ€drugs in combination with immunotherapy and advances in clinical trials. <i>Cancer Communications</i> , 2022, 42, 493-516.	9.2	14
8	CD58 loss in tumor cells confers functional impairment of CAR T cells. <i>Blood Advances</i> , 2022, 6, 5844-5856.	5.2	20
9	Adaptive T cell immunotherapy in cancer. <i>Science China Life Sciences</i> , 2021, 64, 363-371.	4.9	13
10	Clinical development of CAR T cell therapy in China: 2020 update. <i>Cellular and Molecular Immunology</i> , 2021, 18, 792-804.	10.5	50
11	Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-Î³+ CD4+ T Cells Through Enhancing IÎ²BÎ± Degradation and NF-Î²B Activation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 647713.	3.7	4
12	Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 2782-2791.	7.0	21
13	Exploring innate immunity in cancer immunotherapy: opportunities and challenges. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1607-1609.	10.5	19
14	Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. , 2021, 9, e002347.		35
15	Safety and efficacy of chidamide in combination with decitabine plus anti-PD-1 camrelizumab after relapse or progression on decitabine-plus-camrelizumab in classical Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19515-e19515.	1.6	2
16	Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats. <i>Stem Cells and Development</i> , 2021, 30, 502-514.	2.1	1
17	A retrospective study of efficacy and safety of mechlorethamine, vindesine, liposomal doxorubicin, and prednisone (MODP) in relapsed/refractory classical Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19516-e19516.	1.6	0
18	Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 106.	17.0	22

#	ARTICLE	IF	CITATIONS
19	Mutant B2Mâ€HLAâ€E and B2Mâ€HLAâ€G fusion proteins protects universal chimeric antigen receptorâ€modified T cells from allogeneic NK cellâ€mediated lysis. <i>European Journal of Immunology</i> , 2021, 51, 2513-2521.	2.9	15
20	Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. <i>Theranostics</i> , 2021, 11, 4699-4709.	10.0	7
21	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. <i>Nature Communications</i> , 2021, 12, 409.	12.8	109
22	Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 430-432.	10.5	26
23	Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 541330.	2.8	21
24	Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. <i>Cytotherapy</i> , 2020, 22, 573-580.	0.7	77
25	The Role of Posttranslational Modifications in DNA Repair. <i>BioMed Research International</i> , 2020, 2020, 1-13.	1.9	3
26	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 134.	17.1	84
27	Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system. <i>Frontiers of Medicine</i> , 2020, 14, 726-745.	3.4	9
28	Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway. <i>OncImmunology</i> , 2020, 9, 1824643.	4.6	24
29	Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1671.	2.8	25
30	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. <i>Cell Research</i> , 2020, 30, 966-979.	12.0	349
31	Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. , 2020, 8, e000367.		72
32	Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4521-4530.	7.0	15
33	Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092760.	3.2	7
34	Mesenchymal stem cells ameliorate myocardial fibrosis in diabetic cardiomyopathy via the secretion of prostaglandin E2. <i>Stem Cell Research and Therapy</i> , 2020, 11, 122.	5.5	43
35	Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. <i>Science</i> , 2020, 368, .	12.6	716
36	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 30.	17.0	187

#	ARTICLE	IF	CITATIONS
37	Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors.. Journal of Clinical Oncology, 2020, 38, 3038-3038.	1.6	8
38	Combined regimen of inhalable STING agonist plus chemoimmunotherapy in platinum-resistant or platinum-refractory ovarian cancer: A randomized, open-label, phase II trial.. Journal of Clinical Oncology, 2020, 38, 6071-6071.	1.6	1
39	Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma. PeerJ, 2020, 8, e9362.	2.0	3
40	769â€¦CAR T cells undergoing epigenetic reprogramming by low-dose decitabine enhances persistent anti-tumor efficacy in vivo. , 2020, , .		0
41	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39.	10.5	57
42	Decitabine assists umbilical cord-derived mesenchymal stem cells in improving glucose homeostasis by modulating macrophage polarization in type 2 diabetic mice. Stem Cell Research and Therapy, 2019, 10, 259.	5.5	25
43	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. , 2019, 7, 209.		73
44	Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy. Journal of Translational Medicine, 2019, 17, 251.	4.4	71
45	Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Journal of Genetics and Genomics, 2019, 46, 367-377.	3.9	29
46	Target selection for CAR-T therapy. Journal of Hematology and Oncology, 2019, 12, 62.	17.0	118
47	Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. Journal of Hematology and Oncology, 2019, 12, 57.	17.0	46
48	Addition of Low-Dose Decitabine to Antiâ€“PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 1479-1489.	1.6	135
49	Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor. Frontiers in Oncology, 2019, 9, 1196.	2.8	39
50	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. Journal of Hematology and Oncology, 2019, 12, 128.	17.0	106
51	Standardizing CAR-T therapy: Getting it scaled up. Biotechnology Advances, 2019, 37, 239-245.	11.7	35
52	CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. OncoImmunology, 2018, 7, e1440169.	4.6	219
53	Phase Ib/II study of safety and efficacy of lowâ€“dose decitabineâ€“primed chemoimmunotherapy in patients with drugâ€“resistant relapsed/refractory alimentary tract cancer. International Journal of Cancer, 2018, 143, 1530-1540.	5.1	21
54	Effect of Mst1 on Endometriosis Apoptosis and Migration: Role of Drp1-Related Mitochondrial Fission and Parkin-Required Mitophagy. Cellular Physiology and Biochemistry, 2018, 45, 1172-1190.	1.6	46

#	ARTICLE	IF	CITATIONS
55	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	17.0	256
56	Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. <i>Protein and Cell</i> , 2018, 9, 867-878.	11.0	81
57	Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. <i>Protein and Cell</i> , 2018, 9, 516-526.	11.0	46
58	Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. <i>Protein and Cell</i> , 2018, 9, 838-847.	11.0	196
59	Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1277-1286.	7.0	159
60	Infusion of adipose-derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats. <i>Molecular Medicine Reports</i> , 2018, 17, 8466-8474.	2.4	14
61	Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1320-1332.	4.9	11
62	The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice. <i>International Immunopharmacology</i> , 2018, 60, 235-245.	3.8	37
63	Human umbilical cord-derived mesenchymal stem cells direct macrophage polarization to alleviate pancreatic islets dysfunction in type 2 diabetic mice. <i>Cell Death and Disease</i> , 2018, 9, 760.	6.3	60
64	Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. <i>Biomarker Research</i> , 2018, 6, 4.	6.8	184
65	DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1. <i>Journal of Genetics and Genomics</i> , 2018, 45, 205-214.	3.9	30
66	Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 7537-7537.	1.6	2
67	The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. <i>Oncotarget</i> , 2018, 9, 2105-2119.	1.8	29
68	Wnt1a maintains characteristics of dermal papilla cells that induce mouse hair regeneration in a 3D preculture system. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 1479-1489.	2.7	24
69	Mesenchymal stem cell-conditioned medium accelerates wound healing with fewer scars. <i>International Wound Journal</i> , 2017, 14, 64-73.	2.9	77
70	M2 macrophages infusion ameliorates obesity and insulin resistance by remodeling inflammatory/macrophages' homeostasis in obese mice. <i>Molecular and Cellular Endocrinology</i> , 2017, 443, 63-71.	3.2	14
71	Umbilical cord-derived mesenchymal stromal cell-conditioned medium exerts in vitro antiaging effects in human fibroblasts. <i>Cytotherapy</i> , 2017, 19, 371-383.	0.7	26
72	New development in CAR-T cell therapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 53.	17.0	282

#	ARTICLE	IF	CITATIONS
73	Theoretical and practical aspects of using fetal fibroblasts for skin regeneration. <i>Ageing Research Reviews</i> , 2017, 36, 32-41.	10.9	11
74	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. <i>Protein and Cell</i> , 2017, 8, 896-925.	11.0	59
75	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. <i>Protein and Cell</i> , 2017, 8, 861-877.	11.0	53
76	Mesenchymal stem cell therapy in type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 36.	2.7	82
77	The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. <i>Oncolmmunology</i> , 2017, 6, e1323619.	4.6	23
78	Identification of global transcriptome abnormalities and potential biomarkers in eutopic endometria of women with endometriosis: A preliminary study. <i>Biomedical Reports</i> , 2017, 6, 654-662.	2.0	29
79	Spleen-Derived Anti-Inflammatory Cytokine IL-10 Stimulated by Adipose Tissue-Derived Stem Cells Protects Against Type 2 Diabetes. <i>Stem Cells and Development</i> , 2017, 26, 1749-1758.	2.1	14
80	CART trials are going ahead. <i>Science China Life Sciences</i> , 2017, 60, 1276-1279.	4.9	3
81	Increased IFN γ + T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6031-6043.	7.0	42
82	Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 575-586.	7.0	28
83	Mild hyperglycemia triggered islet function recovery in streptozotocin-induced insulin-deficient diabetic rats. <i>Journal of Diabetes Investigation</i> , 2017, 8, 44-55.	2.4	4
84	A Conditioned Medium of Umbilical Cord Mesenchymal Stem Cells Overexpressing Wnt7a Promotes Wound Repair and Regeneration of Hair Follicles in Mice. <i>Stem Cells International</i> , 2017, 2017, 1-13.	2.5	43
85	Extracellular Signal-Regulated Kinase 5 is Required for Low-Concentration H ₂ O ₂ -Induced Angiogenesis of Human Umbilical Vein Endothelial Cells. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	4
86	Preferred M2 Polarization by ASC-Based Hydrogel Accelerated Angiogenesis and Myogenesis in Volumetric Muscle Loss Rats. <i>Stem Cells International</i> , 2017, 2017, 1-13.	2.5	23
87	Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats. <i>Stem Cell Research and Therapy</i> , 2017, 8, 241.	5.5	80
88	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	1.8	115
89	CD133-redirceted chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3042-3042.	1.6	6
90	Granulocyte-Colony Stimulating Factor (G-CSF) Accelerates Wound Healing in Hemorrhagic Shock Rats by Enhancing Angiogenesis and Attenuating Apoptosis. <i>Medical Science Monitor</i> , 2017, 23, 2644-2653.	1.1	30

#	ARTICLE	IF	CITATIONS
91	Blockade of the LRP16-PKR-NF- κ B signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. <i>ELife</i> , 2017, 6, .	6.0	19
92	Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14555-e14555.	1.6	2
93	The Effect of Adipose-Derived Stem Cells on Full-Thickness Skin Grafts. <i>BioMed Research International</i> , 2016, 2016, 1-10.	1.9	16
94	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	2.2	32
95	Insight into Reepithelialization: How Do Mesenchymal Stem Cells Perform?. <i>Stem Cells International</i> , 2016, 2016, 1-9.	2.5	39
96	G-CSF Administration after the Intraosseous Infusion of Hypertonic Hydroxyethyl Starches Accelerating Wound Healing Combined with Hemorrhagic Shock. <i>BioMed Research International</i> , 2016, 2016, 1-9.	1.9	6
97	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	1.8	76
98	DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire. <i>Oncotarget</i> , 2016, 7, 37882-37892.	1.8	22
99	Hypoxia pretreatment of bone marrow-derived mesenchymal stem cells seeded in a collagen-chitosan sponge scaffold promotes skin wound healing in diabetic rats with hindlimb ischemia. <i>Wound Repair and Regeneration</i> , 2016, 24, 45-56.	3.0	74
100	Association between oestrogen receptor alpha (ESR1) gene polymorphisms and endometriosis: a meta-analysis of 24 case-control studies. <i>Reproductive BioMedicine Online</i> , 2016, 33, 335-349.	2.4	15
101	Endometriosis research using capture microdissection techniques: Progress and future applications. <i>Biomedical Reports</i> , 2016, 5, 531-540.	2.0	7
102	An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. <i>Science China Life Sciences</i> , 2016, 59, 379-385.	4.9	14
103	Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. <i>Science China Life Sciences</i> , 2016, 59, 349-359.	4.9	10
104	Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1431-1439.	2.5	14
105	Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 131.	17.0	60
106	Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. <i>Science China Life Sciences</i> , 2016, 59, 1305-1312.	4.9	110
107	Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1601-1610.	1.8	7
108	The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1019-1029.	1.7	15

#	ARTICLE	IF	CITATIONS
109	Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. <i>Stem Cells</i> , 2016, 34, 627-639.	3.2	120
110	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. <i>Science China Life Sciences</i> , 2016, 59, 468-479.	4.9	222
111	Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	212
112	Epithelial-mesenchymal transition: An emerging target in tissue fibrosis. <i>Experimental Biology and Medicine</i> , 2016, 241, 1-13.	2.4	95
113	Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital. <i>Science China Life Sciences</i> , 2016, 59, 1063-1067.	4.9	1
114	Beta-cell regeneration from vimentin+/MafB+ cells after STZ-induced extreme beta-cell ablation. <i>Scientific Reports</i> , 2015, 5, 11703.	3.3	25
115	Mesenchymal stem cell-based therapy for nonhealing wounds: today and tomorrow. <i>Wound Repair and Regeneration</i> , 2015, 23, 465-482.	3.0	39
116	Macroscopic Supramolecular Assembly to Fabricate 3D Ordered Structures: Towards Potential Tissue Scaffolds with Targeted Modification. <i>Advanced Functional Materials</i> , 2015, 25, 6851-6857.	14.9	51
117	Spotlight on decitabine for myelodysplastic syndromes in Chinese patients. <i>OncoTargets and Therapy</i> , 2015, 8, 2783.	2.0	3
118	Hypoxia Pretreatment of Bone Marrow Mesenchymal Stem Cells Facilitates Angiogenesis by Improving the Function of Endothelial Cells in Diabetic Rats with Lower Ischemia. <i>PLoS ONE</i> , 2015, 10, e0126715.	2.5	70
119	Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. <i>Oncotarget</i> , 2015, 6, 33961-33971.	1.8	113
120	Transdifferentiation of Umbilical Cord-Derived Mesenchymal Stem Cells Into Epidermal-Like Cells by the Mimicking Skin Microenvironment. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 136-145.	1.1	14
121	LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. <i>Journal of Translational Medicine</i> , 2015, 13, 308.	4.4	469
122	Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. <i>Journal of Pathology</i> , 2015, 236, 165-174.	4.5	37
123	Substrate stiffness regulates B cell activation, proliferation, class switch, and T cell-independent antibody responses in vivo. <i>European Journal of Immunology</i> , 2015, 45, 1621-1634.	2.9	76
124	Cytokine-induced killer (CIK) cells: from basic research to clinical translation. <i>Chinese Journal of Cancer</i> , 2015, 34, 99-107.	4.9	51
125	An LRP16-containing preassembly complex contributes to NF- κ B activation induced by DNA double-strand breaks. <i>Nucleic Acids Research</i> , 2015, 43, 3167-3179.	14.5	19
126	Mesenchymal Stem Cell-Conditioned Medium Improves the Proliferation and Migration of Keratinocytes in a Diabetes-Like Microenvironment. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 73-86.	1.1	55

#	ARTICLE	IF	CITATIONS
127	Hypoxia Regulates the Therapeutic Potential of Mesenchymal Stem Cells Through Enhanced Autophagy. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 63-72.	1.1	48
128	A negative-feedback function of PKC δ in the formation and accumulation of signaling-active B cell receptor microclusters within B cell immunological synapse. <i>Journal of Leukocyte Biology</i> , 2015, 97, 887-900.	3.3	3
129	Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. <i>OncoImmunology</i> , 2015, 4, e1027469.	4.6	142
130	An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 16698-16711.	1.8	36
131	Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth. <i>Oncotarget</i> , 2015, 6, 22126-22138.	1.8	29
132	Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance. <i>Current Protein and Peptide Science</i> , 2015, 16, 270-278.	1.4	15
133	The Accomplices of NF- κ B Lead to Radioresistance. <i>Current Protein and Peptide Science</i> , 2015, 16, 279-294.	1.4	46
134	Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting β -catenin. <i>Current Protein and Peptide Science</i> , 2015, 16, 301-309.	1.4	55
135	Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. <i>Current Protein and Peptide Science</i> , 2015, 16, 329-336.	1.4	15
136	Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report. <i>Journal of Immunology Research</i> , 2014, 2014, 1-14.	2.2	52
137	lncRNAs: Insights into their function and mechanics in underlying disorders. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 762, 1-21.	5.5	196
138	Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. <i>Cancer Letters</i> , 2014, 354, 12-20.	7.2	98
139	Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. <i>Human Molecular Genetics</i> , 2014, 23, 6008-6021.	2.9	59
140	Treatment of MSCs with Wnt1 α -conditioned medium activates DP cells and promotes hair follicle regrowth. <i>Scientific Reports</i> , 2014, 4, 5432.	3.3	64
141	The macrodomain family: Rethinking an ancient domain from evolutionary perspectives. <i>Science Bulletin</i> , 2013, 58, 953-960.	1.7	0
142	Culturing on Wharton's Jelly Extract Delays Mesenchymal Stem Cell Senescence through p53 and p16INK4a/pRb Pathways. <i>PLoS ONE</i> , 2013, 8, e58314.	2.5	36
143	The macro domain protein family: Structure, functions, and their potential therapeutic implications. <i>Mutation Research - Reviews in Mutation Research</i> , 2011, 727, 86-103.	5.5	104
144	DNA damage stress induces the dissociation of Smurf1/2 from MDM2 in a slow manner. <i>Science Bulletin</i> , 2011, 56, 3155.	1.7	3

#	ARTICLE	IF	CITATIONS
145	LRP16 Integrates into NF- κ B Transcriptional Complex and Is Required for Its Functional Activation. PLoS ONE, 2011, 6, e18157.	2.5	32
146	Acclimatized Induction Reveals the Multipotency of Adult Human Undifferentiated Keratinocytes. Cellular Reprogramming, 2010, 12, 283-294.	0.9	5
147	FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells. Nucleic Acids Research, 2009, 37, 3996-4009.	14.5	19